Tavulus (tiotropium bromide) DPI was launched in Spain to treat chronic obstructive pulmonary disease(COPD)

MUMBAI, India, Oct. 11, 2021

Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company today announced the launch of a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name Tavulus® in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).

In November 2017, a Glenmark European subsidiary entered into a strategic, exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and the UK.

Glenmark is planning subsequent launches of the product across these markets under the brand name :

• Tiogiva® in UK, Ireland, Sweden, Finland and Norway;
• Tavulus® in Denmark and Netherlands;
• and Tiotropium Glenmark® in Germany.

Tavulus®Tiotropium Bromide dry powder inhaler (DPI) is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.

Chronic Obstructive Pulmonary Disease（COPD） is a long-term condition that causes inflammation in the lungs, damaging the lung tissue and narrowing the airways, all of which make breathing difficult. Studies show that close to 2.5 million people suffer from COPD in Spain.

SOURCE

https://www.prnewswire.com/in/news-releases/glenmark-launches-tavulus-r-for-copd-treatment-in-spain-becoming-one-of-the-first-companies-to-launch-a-bioequivalent-version-of-the-dry-powder-inhaler-875668974.html